Effects of the somatostatin analog, octreotide, on glucose metabolism and insulin sensitivity in insulin-dependent diabetes mellitus

Metabolism: Clinical and Experimental

Volumn 45, Issue 2, 1996, Pages 211-217

  Orskov L ^a   Moller N ^b   Bak, J F ^b   Porksen N ^b   Schmitz, O ^b  

^a AARHUS UNIVERSITY HOSPITAL   (Denmark)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

FATTY ACID; GLUCOSE; GROWTH HORMONE; INSULIN; OCTREOTIDE; SOMATOMEDIN C;

ADULT; ARTICLE; CALORIMETRY; CLINICAL ARTICLE; DOSE RESPONSE; GLUCOSE BLOOD LEVEL; GLUCOSE CLAMP TECHNIQUE; GLUCOSE METABOLISM; GLUCOSE TRANSPORT; GLYCOGENOLYSIS; HUMAN; HUMAN TISSUE; HYPERINSULINEMIA; INSULIN DEPENDENT DIABETES MELLITUS; INSULIN SENSITIVITY; LIPID OXIDATION; MALE; MUSCLE BIOPSY; PRIORITY JOURNAL; SUBCUTANEOUS DRUG ADMINISTRATION;

EID: 0029989475     PISSN: 00260495     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0026-0495(96)90056-6     Document Type: Article

References (46)

1. Ørskov H, Grønbæk H, Skjærbæk C, et al: Possible effects and mechanisms of action of IGF-I in the development of diabetic complications, in Sakamoto N, Alberti KGMM, Hotta N (eds): Pathogenesis and Treatment of NIDDM and Its Related Problems. Proceedings of the Fourth International Symposium on the Treatment of Diabetes Mellitus. Nagoya, Japan, Oct 26-27, 1993. Amsterdam, The Netherlands, Excerpta Medica, 1994, pp 83-89
2. Ezzat S, Melmed S: Endocrine applications of the somatostatin analogue octreotide (Sandostatin). Metabolism 41:34-38, 1992 (suppl 2)
3. Marshall S, Alberti KGMM: Alterations in the growth hormone/insulin-like growth factor I axis in human and experimental diabetes: Differences and similarities, in Flyvbjerg A, Ørskov H, Alberti KGMM (eds): Growth Hormone and Insulin-Like Growth Factor I in Human and Experimental Diabetes, vol 1. New York, NY, Wiley, 1993, pp 23-46
4. Sonksen PH, Russel-Jones D, Jones RH: Growth hormone and diabetes mellitus. A review of sixty-three years of medical research and a glimpse into the future? Horm Res 40:68-79, 1993
5. Gerich JE: Role of somatostatin and its analogues in the pathogenesis and treatment of diabetes mellitus. Metabolism 39:52-54, 1990
6. Bauer W, Briner U, Doepfner W, et al: SMS 201-995: A very potent and selective octapeptide analogue of somatostatin with prolonged action. Life Sci 31:1133-1140, 1983
7. Serrano Rios M, Navascues I, Saban J, et al: Somatostatin analog SMS 201-995 and insulin needs in insulin-dependent diabetic patients studied by means of an artificial pancreas. J Clin Endocrinol Metab 63:1071-1074, 1986
8. Grossman LD, Shumak SL, George SR, et al: The effects of SMS 201-995 (Sandostatin) on metabolic profiles in insulin-dependent diabetes mellitus. J Clin Endocrinol Metab 68:63-67, 1989
9. Kirkegaard C, Norgaard K, Snorgaard O, et al: Effect of one year continuous subcutaneous infusion of a somatostatin analogue, octreotide, on early retinopathy, metabolic control and thyroid function in type I (insulin-dependent) diabetes mellitus. Acta Endocrinol (Copenh) 122:766-772, 1990
10. Hyer SL, Sharp PS, Brooks RA, et al: Continuous subcutaneous octreotide infusion markedly suppresses IGF-I levels whilst only partially suppressing GH secretion in diabetics with retinopathy. Acta Endocrinol (Copenh) 120:187-194, 1989
11. Plewe G, Noelken G, Krause U, et al: Suppression of growth hormone and somatomedin C by long-acting somatostatin analog SMS 201-995 in type I diabetes mellitus. Horm Res 27:7-12, 1987
12. Osei K, O'Dorisio TM, Malarkey WB, et al: Metabolic effects of long-acting somatostatin analogue (Sandostatin) in type I diabetic patients on conventional therapy. Diabetes 38:704-709, 1989
13. Laws A, Reaven GM: Evidence for an independent relationship between insulin resistance and fasting HDL cholesterol, triglyceride, and insulin concentrations. J Intern Med 231:25-30, 1992
14. Laakso M, Sarlund H, Salonen R, et al: Asymptomatic atherosclerosis and insulin resistance. Arterioscler Thromb 11:1068-1076, 1991
15. Ferrannini E, Buzzigoli G, Bonadonna R, et al: Insulin resistance in essential hypertension. N Engl J Med 317:350-357, 1987
16. Frayn KN: Calculation of substrate oxidation rates in vivo from gaseous exchange. J Appl Physiol 55:628-634, 1983
17. Bak JF, Møller N, Schmitz O: Effects of growth hormone on fuel utilization and muscle glycogen synthase activity in normal humans. Am J Physiol 260:E736-E742, 1991
18. Ørskov H, Thomsen HG, Yde H: Wick chromatography for rapid and reliable immunoassay of insulin, glucagon and growth hormone. Nature 219:193-195, 1968
19. Frystyk J, Dinesen B, Ørskov H: Non-competitive timeresolved immunofluorometric assay for determination of human insulin-like growth factor I and II. Growth Reg (in press)
20. Harrison J, Hodson AW, Skillen AW, et al: Blood glucose, lactate, pyruvate, glycerol, 3-hydroxybutyrate and acetoacetate measurements in man using a centrifugal analyser with a fluorimetric attachment. J Clin Chem Clin Biochem 26:141-146, 1988
21. Bak JF, Pedersen O: Exercise-enhanced activation of glycogen synthase in human skeletal muscle. Am J Physiol 258:E957-E963, 1990
22. Kochan RG, Lamb DR, Lutz DR, et al: Glycogen synthase activation in human skeletal muscle: Effects of diet and exercise. Am J Physiol 236:E660-E666, 1979
23. Steele R: Influence of glucose loading and of injected insulin on hepatic glucose output. Ann NY Acad Sci 82:420-424, 1959
24. De Bodo R, Steele R, Altschuler N, et al: On the hormonal regulation of carbohydrate metabolism: Studies with C14 glucose. Recent Prog Horm Res 19:445-488, 1963
25. Yki-Jarvinen H, Consoli A, Nurjhan N, et al: Mechanism for the underestimation of isotopically determined glucose disposal. Diabetes 38:744-751, 1989
26. Bergman RN, Finegood DT, Ader M: Assessment of insulin sensitivity in vivo. Endocr Rev 6:45-84, 1985
27. Christensen SE, Weeke J, Ørskov H, et al: Continuous subcutaneous pump infusion of somatostatin analogue SMS 201-995 versus subcutaneous injection schedule in acromegalic patients. Clin Endocrinol (Oxf) 27:297-306, 1987
28. Spinas GA, Bock A, Keller U: Reduced postprandial hyperglycemia after subcutaneous injection of a somatostatin-analogue (SMS 201-995) in insulin-dependent diabetes mellitus. Diabetes Care 8:429-435, 1985
29. Johanson C, Wisen O, Efendic S, et al: Effects of somatostatin on gastrointestinal propagation and absorption of oral glucose in man. Digestion 22:126-137, 1981
30. Bayraktar M, Usman A, Koray Z: Effect of the new somatostatin analogue SMS 201-995 on exogenously used insulin. Clin Invest 72:669-672, 1994
31. Ho KKY, Jenkins AB, Furler SM, et al: Impact of octreotide, a long-acting somatostatin analogue, on glucose tolerance and insulin sensitivity in acromegaly. Clin Endocrinol (Oxf) 36:271-279, 1992
32. 13C]NMR studies of the effect of the somatostatin analogue octreotide on hepatic glycogenesis and glycogenolysis. Peptides 15:1223-1227, 1994
33. Ogihara M, Ui M: Effects of somatostatin on liver glycogen and fat metabolism in vivo. Jpn J Pharmacol 34:313-318, 1984
34. Hansen I, Tsalikian E, Beaufrere B, et al: Insulin resistance in acromegaly: Defects in both hepatic and extrahepatic insulin action. Am J Physiol 250:E269-E273, 1986
35. Rizza RA, Mandarino LJ, Gerich JE: Effects of growth hormone on insulin action in man. Mechanisms of insulin resistance, impaired suppression of glucose production, and impaired stimulation of glucose utilisation. Diabetes 31:663-669, 1982
36. Møller N, Butler PC, Antsiferov M, et al: Effects of growth hormone on insulin sensitivity and forearm metabolism in normal man. Diabetologia 32:105-110, 1989
37. Randle PJ, Hales CN, Garland PB, et al: The glucose fatty-acid cycle. Its role in insulin sensitivity and the metabolic disturbances of diabetes mellitus. Lancet 1:785-789, 1963
38. Rizza RA, Mandarino LJ, Genest J, et al: Production of insulin resistance by hyperinsulinaemia in man. Diabetologia 28:70-75, 1985
39. Møller N, Bagger JP, Schmitz O, et al: Somatostatin enhances insulin stimulated glucose uptake in the perfused human forearm. J Clin Endocrinol Metab 80:1789-1793, 1995
40. Thiebaud D, Jacot E, DeFronzo RA, et al: The effect of graded doses of insulin on total glucose uptake, glucose oxidation, and glucose storage in man. Diabetes 31:957-963, 1982
41. Davies RR, Miller M, Turner SJ, et al: Effects of somatostatin analogue SMS 201-995 in non-insulin-dependent diabetes. Clin Endocrinol (Oxf) 25:739-747, 1986
42. Johnston DG, Davies RR, Turner SJ: Effects of somatostatin and SMS 201-995 on carbohydrate metabolism in normal man. Scand J Gastroenterol [Suppl] 119:158-165, 1986
43. Felig P: Amino acid metabolism in man. Annu Rev Biochem 44:993-999, 1975
44. Wahren J, Eriksson LS: The influence of a long-acting somatostatin analogue on splanchnic haemodynamics and metabolism in healthy subjects and patients with liver cirrhosis. Scand J Gastroenterol [Suppl] 119:103-108, 1989
45. Wolthers T, Grçfte T, Ørskov H, et al: Effect of lanreotide, a somatostatin analog, on urea synthesis in normal man. Clin Nutr 13:34-37, 1994
46. Navascues I, Gil J, Pascau C, et al: Severe hypoglycemia as a short-term side-effect of the somatostatin analog SMS 201-995 in insulin-dependent diabetes mellitus. Horm Metab Res 20:749-750, 1988